Delving into the Latest Updates on Teikoku Hormone Manufacturing Co., Ltd. with Synapse

Overview

Tags

Immune System Diseases

Endocrinology and Metabolic Disease

Eye Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	1
Immune System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

PPARα(Peroxisome proliferator-activated receptor α)	1

PGE₁ [745-65-3] and PGE₂ [363-24-6], but not PGF_2α [551-11-1], dose-dependently potentiated pain provoked by subliminal arterial doses of bradykinin (I) [58-82-2]; the potentiating doses of prostaglandins did not cause pain themselves.PGE₁ was more potent than PGE₂.Aspirin [50-78-2], phenylbutazone [50-33-9], indomethacin [53-86-1], and ibuprofen [15687-27-1] (200; 15 and 60; 5 and 20; and 25 and 100 mg/kg, i.p., resp.) inhibited I-induced pain, but even at higher doses did not inhibit pain produced by concomitant I and PGE₁ (1.5 μg).Morphine-HCl [52-26-6] (8 mg/kg, s.c.) inhibited I-induced pain responses whether PGE₁ was present or not.Amidopyrine [58-15-1] inhibited pain induced by I alone or with PGE₁, but was less potent against the combination.PGE₁ and PGE₂, but not PGF_2α, potentiated induction of pain when kinin and prostaglandin were arterially injected together.Thus, nonsteroidal antiinflammatory drugs may produce analgesia by preventing prostaglandin formation, and this may be distinguishable from other types of analgesia (e.g. from morphine).Amidopyrine may act in part on spinal or peripheral sites to prevent prostaglandin formation.

12 Apr 2011·Journal of Pharmacy and PharmacologyQ3 · MEDICINE

Anti-hypertensive Effect of Oral Controlled-release Microspheres Containing an ACE Inhibitor (Delapril Hydrochloride) in Rats

Q3 · MEDICINE

Article

Author: Akiyama, Yohko ; Yoshioka, Minoru ; Inada, Yoshiyuki ; Hirai, Shinichiro ; Horibe, Hidetoshi ; Kitamori, Nobuyuki ; Toguchi, Hajime

AbstractAn oral controlled-release drug delivery system based on microspheres of polyglycerol esters of fatty acids (PGEFs), was applied to an anti-hypertensive, delapril hydrochloride. The in-vitro release profile was controlled by selecting a PGEF with an appropriate hydrophilic-lipophilic balance value for the matrix. The microspheres from which 80% of the drug was released in 6 h were orally administered to rats. The plasma concentration of the active metabolite was sustained after administration of the microspheres in comparison with administration of a solution. The in-vivo release profile was in good agreement with the in-vitro release profile. When the microspheres were administered, the pharmacological effect of delapril hydrochloride on the angiotensin I-induced pressor response was also sustained showing consistency with the plasma concentration-time curve.

22 Aug 2007·Journal of Ethology

The lower salivary testosterone levels among unmarried and married sexually active men

Author: M. Oki ; S. Honma ; H. Uehara ; T. Hasegawa ; K. Sakaguchi

We examined the influences of regular sexual activity and marital status on salivary testosterone levels in healthy adult Japanese men. Forty-four men (20–66 years) collected their saliva thrice a day (0900–1000, 1300–1400, and 1700–1800). The testosterone levels at each collection time negatively correlated with the ages of the participants; therefore, residual testosterone levels were used for analyses after correcting for age by linear regression. The testosterone-lowering effect of marriage was marginal and the regular sexual activity more strongly associated with lower testosterone levels in morning saliva. The possible neurofeedback systems underlying the phenomenon are discussed.

100 Deals associated with Teikoku Hormone Manufacturing Co., Ltd.

Login to view more data

100 Translational Medicine associated with Teikoku Hormone Manufacturing Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

1

7

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Fenofibrate ( PPARα )	-	Approved
TZN-13 ( ER )	Menopausal syndrome More	Discontinued
Oberadilol Monoethyl Maleate ( PDE3 x β-adrenoceptors )	Heart Failure More	Discontinued
TZC-1370 ( β-adrenoceptors )	Hypertension More	Discontinued
GP-1447 ( AKR1B1 )	Diabetic Foot More	Pending